Physician profile
Andrea Diane Mccabe
NPI 1710645544
$251.53
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $252.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $69.91 | 2022 | |
| Optinose US, INC. | $31.47 | 2022 | |
| Mylan Specialty L.P. | $28.10 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.55 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $25.28 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $16.91 | 2022 | |
| Aimmune Therapeutics, INC. | $14.30 | 2022 | |
| Horizon Therapeutics Plc | $13.18 | 2022 | |
| Kaleo, INC. | $12.96 | 2022 | |
| Csl Behring | $12.87 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrea Mccabe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.